We compared vascular and metabolic responses (and adverse responses) to statin and fibrate therapies alone or in combination in patients with combined hyperlipidemia. BACKGROUND The mechanisms of action for statins and fibrates are distinct.
High serum cholesterol and elevated low-density lipoprotein (LDL) cholesterol are important risk factors for coronary heart disease. Many patients on statin therapy have initial or recurrent coronary heart disease events despite reductions in LDL cholesterol (1) . Interestingly, fibrate therapy, which significantly decreases triglycerides and increases high-density lipoprotein (HDL) cholesterol without reducing LDL cholesterol, is associated with significant decreases in coronary events (2) . Moreover, combined therapy with statins and fibrates is more effective in controlling atherogenic dyslipidemia in patients with combined hyperlipidemia than the administration of either drug alone (3) . Of concern is the fact that the combination of statins and fibrates is more likely to be accompanied by severe myopathy (4) . This limitation is not observed with fenofibrate, and no significant side effects have been reported with combined statin and fenofibrate treatment (3) (4) (5) .
Coronary heart disease frequently is associated with insulin resistance and metabolic disorders, such as obesity and combined hyperlipidemia. Endothelial dysfunction associated with cardiovascular diseases may contribute to insulin resistance (6) . The effects of statins on insulin resistance are controversial (7, 8) . Peroxisome proliferatoractivated receptor-alpha activators improve insulin sensitivity in rodents (9) . The impact of atovastatin and fenofibrate therapies on endothelial homeostasis and insulin resistance may differ because the mechanisms underlying the biological actions of these drugs are distinct. Therefore, we investigated whether combined therapy has additive beneficial effects greater than atovastatin or fenofibrate alone in patients with combined hyperlipidemia.
METHODS
Study population and design. Fifty-six patients with combined hyperlipidemia (total cholesterol Ն200 mg/dl and triglycerides ranging from 200 mg/dl to 800 mg/dl) participated in this study. We excluded patients with overt liver disease, chronic renal failure, hypothyroidism, myopathy, uncontrolled diabetes, severe hypertension, stroke, acute coronary events, coronary revascularization within the preceding three months, or evidence of alcohol abuse. Clinical characteristics of the study patients are summarized in Table  1 . We administered atorvastatin 10 mg and placebo, atorvastatin 10 mg and fenofibrate 200 mg, or fenofibrate 200 mg and placebo daily during two months in a randomized, double-blind, placebo-controlled crossover trial with three treatment arms (each two months in duration) and two washout periods (each two months in duration). Patients were observed at 14-day intervals (or more frequently) during the study. To avoid side effects, we measured serum asparate aminotransferase, alanine aminotransferase, creatine kinase, blood urea nitrogen, and creatinine before and after therapy. Calcium channel or beta adrenergic blockers were withheld for Ն48 h before the study. The study was approved by the Gil Hospital Institute Review Board, and all participants gave written, informed consent. Laboratory assays. Blood samples were obtained at 8:00 AM after an overnight fast before and after each two-month treatment period. Samples were immediately coded so that investigators performing laboratory assays were blinded to subject identity or study sequence. Assays for lipids, glucose, and plasma adiponectin were performed in duplicate by enzyme-linked immunosorbent assay (R & D Systems, Inc., Minneapolis, Minnesota), assays for high-sensitivity C-reactive protein levels by latex agglutination (CRPLatex(II), Denka-Seiken, Japan), and assays for plasma insulin levels by immunoradiometric assay (INSULIN-RIABEAD II, Abbott Japan, Japan) as described previously (10, 11) . The Quantitative Insulin-Sensitivity Check Index (QUICKI), a surrogate index of insulin sensitivity, was calculated as follows: QUICKI ϭ 1/[log(insulin) ϩ log(glucose)] (12). Vascular studies. Imaging studies of the right brachial artery were performed using an ATL HDI 3000 ultrasound machine (Bothell, Washington) equipped with a 10-MHz linear-array transducer, on the basis of a published technique (10, 11 Values are expressed as means Ϯ SEM or n (%). Table 2 . 
RESULTS
No significant differences among baseline values before each treatment period or carryover effects were noted (Tables 2  and 3) . Effects on lipids. Fenofibrate alone or combined therapy significantly lowered triglycerides and increased HDL cholesterol and apolipoprotein A-I levels when compared with atorvastatin alone (Fig. 1, Table 2 ). Effects on vasomotor function. Atorvastatin, combined therapy, or fenofibrate significantly improved the percent flow-mediated dilator response to hyperemia relative to baseline measurements by 46 Ϯ 9%, 81 Ϯ 12%, and 45 Ϯ 5%, respectively (all p Ͻ 0.001). Of note, combined therapy significantly improved this response more than atorvastatin or fenofibrate alone (p Ͻ 0.001 by ANOVA) (Fig. 2, Table 2 ). Brachial artery dilator response to nitroglycerin was not significantly changed from respective baseline values. After combined therapy, improvement in flow-mediated dilation (FMD) correlated with changes in total cholesterol (r ϭ Ϫ0.373 and p ϭ 0.005), triglycerides (r ϭ Ϫ0.288 and p ϭ 0.032), and apolipoprotein B levels (r ϭ Ϫ0.341, p ϭ 0.010). Effects on acute-phase reactants. Atorvastatin, combined therapy, or fenofibrate significantly lowered plasma highsensitivity C-reactive protein levels relative to baseline measurements from 1.20 to 0.75 (p ϭ 0.006), 1.20 to 0.60 Table 3 . Fenofibrate alone or combined therapy significantly lowered plasma fibrinogen levels relative to baseline measurements (both p Ͻ 0.001). Of note, combined therapy significantly reduced this more than atorvastatin alone (p ϭ 0.015 by ANOVA) (Fig. 3 , Table 2 ). Effects on adiponectin and insulin resistance. There were significant inverse correlations between baseline adiponectin and baseline triglycerides (r ϭ Ϫ0.277, p ϭ 0.039 before atorvastatin; r ϭ Ϫ0.335, p ϭ 0.012 before combined therapy; and r ϭ Ϫ0.288, p ϭ 0.032 before fenofibrate). There were significant correlations between baseline adiponectin and baseline HDL cholesterol (r ϭ 0.284, p ϭ 0.034 before atorvastatin; r ϭ 0.258, p ϭ 0.049 before combined therapy; and r ϭ 0.353, p ϭ 0.008 before fenofibrate). However, there were no significant correlations between baseline adiponectin and baseline insulin or QUICKI. Combined therapy or fenofibrate alone significantly increased plasma adiponectin levels relative to baseline measurements from 3.4 to 3.5 (p ϭ 0.001) and 3.2 to 3.6 (p ϭ 0.004), respectively. These increases were significantly greater than those observed with atorvastatin alone (p ϭ 0.022 by ANOVA) (Fig. 4, Table 3 ). The three therapies did not have significantly different baseline insulin and glucose levels. However, the magnitude of reduction of insulin with combined therapy was significantly greater than with atorvastatin alone (p ϭ 0.012 by ANOVA) ( Table 3) . Combined therapy or fenofibrate alone significantly increased QUICKI relative to baseline measurements by 7 Ϯ 2% (p ϭ 0.003) and 5 Ϯ 2% (p ϭ 0.043), respectively. These increases with combined therapy were significantly greater than those observed with atorvastatin alone (p ϭ 0.049 by ANOVA) (Fig. 4, Table 3 ). There were significant correlations between percent changes in adiponectin and percent changes in QUICKI (r ϭ 0.283, p ϭ 0.034) or apolipoprotein A-I (r ϭ 0.351, p ϭ 0.008), and there were significant inverse correlations between percent changes in adiponectin and percent changes in insulin (r ϭ Ϫ0.332, p ϭ 0.013) after combined therapy. However, there were no significant correlations between percent changes in adiponectin levels and percent changes in triglycerides (r ϭ 0.085) or HDL cholesterol levels (r ϭ Ϫ0.048). Safety and adverse effects. No patients were withdrawn from the study because of serious adverse effects (Table 4) . Elevations in liver and muscle enzymes and gastrointestinal upset were mainly transient and resolved spontaneously after patients finished the study. Liver enzymes 41-120 IU 4 (7) 8 (14) 4 (7) Liver enzymes 121-136 IU
Creatine kinase 201-629 IU 1 (2) 4 (7) 2 (4) Gastrointestinal upset 2 (4) 5 (9) 4 (7) Upper limits of normal of liver enzymes (serum aminotransferases: alanine and aspartate) and creatine kinase are 40 IU and 200 IU, respectively.
DISCUSSION
In patients with combined hyperlipidemia, atorvastatin and fenofibrate therapy alone changed the lipoprotein profiles as expected. We reasoned that distinct biological actions of atorvastatin and fenofibrate therapies on lipoproteins, fibrinogen, adiponectin, and insulin sensitivity may improve endothelium-dependent vascular function by different mechanisms. Indeed, although monotherapy with atorvastatin or fenofibrate significantly improved lipid profiles, endothelial function, inflammatory markers, and insulin sensitivity, combined therapy had additional substantial and significant beneficial effects on these parameters over those seen with monotherapy for either drug. The enhanced vascular reactivity we observed with combination therapy may be the result of both changes in lipoprotein profiles as well as other effects, including pleiotropic actions of statins and actions of fenofibrate to increase nitric oxide production (13) . Importantly, no patients were withdrawn from our study as the result of serious adverse effects. Fenofibrate therapy alone resulted in significant elevation of adiponectin levels, decreased insulin levels, and increased insulin sensitivity (assessed by QUICKI). The present study is the first report demonstrating that fenofibrate therapy can increase adiponectin levels. Adiponectin is an adiposederived factor that augments and mimics metabolic actions of insulin. Moreover, adiponectin can directly stimulate nitric oxide production from endothelium (14) . Therefore, increasing adiponectin levels would be predicted to improve both insulin sensitivity and endothelial function by multiple mechanisms. Interestingly, in contrast to effects of combination therapy on FMD, the beneficial effects of fenofibrate therapy on adiponectin levels, insulin levels, and insulin sensitivity did not increase further with combination therapy. Thus, the benefits with respect to insulin resistance are predominantly the result of fibrate therapy rather than statin therapy, which suggests that improving endothelial function per se (as reflected by FMD) may not completely explain effects of fenofibrate or combined therapy to improve insulin sensitivity. However, combined therapy may reduce insulin resistance by multiple mechanisms such as lipoprotein changes and peroxisome proliferator-activated receptoralpha activators. Fenofibrate or combined therapy for two months increased adiponectin levels without a change in body weight or body mass index, which raises the possibility that drug therapy is directly altering adiponectin levels independent of adiposity. It is possible that monotherapy with doses of statins higher than those used in our present study may have additional benefits similar to those we observed with our combined fibrate/statin therapy. However, caution is indicated because recent clinical studies suggest high doses of statins may increase the onset of new diabetes (15) . In summary, our study suggests that combined atorvastatin/fenofibrate therapy is safe and has beneficial additive effects, supporting the updated National Cholesterol Education Program Adult Treatment Panel III guidelines (16) .
